Pharmacogenetic (PGx) analysis of toxicity after oxaliplatin (Ox), capecitabine (Cap), bevacizumab (Bev) and cetuximab (Cet) therapy for advanced colorectal cancer (ACC): First results from the Dutch Colorectal Cancer Group (DCCG)-CAIRO2 trial

Autor:	H. Gelderblom, Henk-Jan Guchelaar, R. J. van der Straaten, J. Pander, Jolien Tol, C.J.A. Punt, Ninja Antonini
Rok vydání:	2008
Předmět:	Oncology Cancer Research medicine.medical_specialty Bevacizumab Cetuximab Colorectal cancer business.industry Pharmacology medicine.disease Oxaliplatin Capecitabine Advanced colorectal cancer Internal medicine Toxicity medicine business Pharmacogenetics medicine.drug
Zdroj:	Journal of Clinical Oncology. 26:2574-2574
ISSN:	1527-7755 0732-183X
Popis:	2574 Background: In the CAIRO2 study the addition of Cet to the combination Cap, Ox and Bev for patients with untreated ACC is investigated. The aim of this side study is to evaluate predictive PGx...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::3fa4adf76915328c14e2bb0fb2c58fd9 https://doi.org/10.1200/jco.2008.26.15_suppl.2574 Zobrazit plný text záznamu